Hemispherx Expands Community and Physician Involvement

Philadelphia (PROTEXT) - Hemispherx Biopharma (Amex: HEB) saidtoday that in response to approaches by physicians, the AidsCooperative Treatment Groups (ACTG -- the major Federally fundednationwide organization of clinical experts in AIDS), and otherpatient advocacy groups, the company is evaluating proposals tosupport the formation of independent Community Advisory Boardsfor both the CFIDS and HIV disease categories. Community Advisory Boards (CAB) are independent groups formedto facilitate communications among physicians, patient advocatesand drug development companies. CABs have provided importantinput to numerous pharmaceutical companies, including suchmultinational leaders as Merck, DuPont and Glaxo Wellcome. SomeCABs receive initial funding from pharmaceutical companies toassist them in their early organizational stages. There is alsoFederal funding available for certain CABs that deal withseverely debilitating or life threatening diseases, such as AIDS. The current movement to form CABs to facilitate physician andpatient advocate communications with Hemispherx has gainedmomentum from recent articles in The New England Journal ofMedicine that describe the emergence of multi-drug resistantstrains of HIV and call for research and development intopotential treatments with new mechanisms of action to combatthese new viral strains for which presently available drugs mayhave limited utility. Hemispherx said that it would invite senior physicians fromthe Food and Drug Administration as well as internationallyrecognized AIDS clinical experts from ACTG to participate in allscientific and educational meetings with the CABs once theirformation is complete. Hemispherx said that the prospective community members of thenew CABs are highly experienced patient advocates who sit onCommunity Advisory Boards of other leading drug companies andhave decades-long commitment to their respective serviceorganizations including ACT UP. Hemispherx is a biopharmaceutical company specializing in newtherapeutic approaches to HIV/AIDS, CFS (Chronic FatigueSyndrome) and hepatitis B/C utilizing the immune system. It hasoffices in Philadelphia, Belgium and France and new drugdevelopment facilities in the Washington D.C. area. Information contained in this news release other thanhistorical information, should be considered forward-looking andis subject to various risk factors and uncertainties. Forinstance, the strategies and operations of Hemispherx involverisks of competition, changing market conditions, changes in lawsand regulations affecting these industries and numerous otherfactors discussed in this release and in the Company's filingswith the Securities and Exchange Commission. Accordingly, actualresults may differ materially from those in any forward-lookingstatements. ots Original Text Service: Hemispherx Biopharma,Inc. Internet: http://www.newsaktuell.de Contact: William A.Carter, M.D., CEO & Chairman of Hemispherx Biopharma, Inc.(USA) 215-988-0080; or William Jenks, Media (USA) 212-232-2222,Fax, (USA) 212-232-3232; or Sharon Will, Investor Relations(USA) 212-572-0762, Fax, (USA) 212-572-0764, for HemispherxBiopharma, Inc. Web site: http://www.hemispherx.com

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.

PROTEXT